

Michael Spedding

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2993034/publications.pdf>

Version: 2024-02-01

189
papers

21,122
citations

15495

65
h-index

9579

142
g-index

194
all docs

194
docs citations

194
times ranked

27264
citing authors

#	ARTICLE	IF	CITATIONS
1	The IUPHAR/BPS guide to PHARMACOLOGY in 2022: curating pharmacology for COVID-19, malaria and antibacterials. <i>Nucleic Acids Research</i> , 2022, 50, D1282-D1294.	6.5	99
2	Aging, VO ₂ max, entropy, and COVID-19. <i>Indian Journal of Pharmacology</i> , 2022, 54, 58.	0.4	3
3	Phenotypical Screening on Neuronal Plasticity in Hippocampal-Prefrontal Cortex Connectivity Reveals an Antipsychotic with a Novel Profile. <i>Cells</i> , 2022, 11, 1181.	1.8	1
4	Brain circuits at risk in psychiatric diseases and pharmacological pathways. <i>Therapie</i> , 2021, 76, 75-86.	0.6	2
5	Sphingolipids metabolism alteration in the central nervous system: Amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. <i>Seminars in Cell and Developmental Biology</i> , 2021, 112, 82-91.	2.3	28
6	Class A Orphans in GtoPdb v.2021.3. IUPHAR/BPS Guide To Pharmacology CITE, 2021, 2021, .	0.2	3
7	Ionotropic glutamate receptors in GtoPdb v.2021.3. IUPHAR/BPS Guide To Pharmacology CITE, 2021, 2021, .	0.2	0
8	THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Introduction and Other Protein Targets. <i>British Journal of Pharmacology</i> , 2021, 178, S1-S26.	2.7	183
9	The IUPHAR/BPS Guide to PHARMACOLOGY in 2020: extending immunopharmacology content and introducing the IUPHAR/MMV Guide to MALARIA PHARMACOLOGY. <i>Nucleic Acids Research</i> , 2020, 48, D1006-D1021.	6.5	131
10	Drug repositioning in neurodegeneration: An overview of the use of ambroxol in neurodegenerative diseases. <i>European Journal of Pharmacology</i> , 2020, 884, 173446.	1.7	9
11	A rational roadmap for SARS-CoV-2/COVID-19 pharmacotherapeutic research and development: IUPHAR Review 29. <i>British Journal of Pharmacology</i> , 2020, 177, 4942-4966.	2.7	61
12	The IUPHAR Guide to Immunopharmacology: connecting immunology and pharmacology. <i>Immunology</i> , 2020, 160, 10-23.	2.0	7
13	Cognition- and circuit-based dysfunction in a mouse model of 22q11.2 microdeletion syndrome: effects of stress. <i>Translational Psychiatry</i> , 2020, 10, 41.	2.4	18
14	Guide to Immunopharmacology: a database to boost immunology education, research and therapy. <i>Immunology</i> , 2020, 160, 1-2.	2.0	1
15	Class A Orphans (version 2020.5) in the IUPHAR/BPS Guide to Pharmacology Database. IUPHAR/BPS Guide To Pharmacology CITE, 2020, 2020, .	0.2	7
16	THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Introduction and Other Protein Targets. <i>British Journal of Pharmacology</i> , 2019, 176, S1-S20.	2.7	295
17	Ambroxol Hydrochloride Improves Motor Functions and Extends Survival in a Mouse Model of Familial Amyotrophic Lateral Sclerosis. <i>Frontiers in Pharmacology</i> , 2019, 10, 883.	1.6	31
18	Plan S: A threat to quality of science?. <i>Science</i> , 2019, 363, 462-462.	6.0	4

#	ARTICLE	IF	CITATIONS
19	The age-performance relationship in the general population and strategies to delay age related decline in performance. Archives of Public Health, 2019, 77, 51.	1.0	22
20	Age-Related Upper Limits in Physical Performances. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2019, 74, 591-599.	1.7	10
21	Scientists on the Spot: the Guide to Immunopharmacology as a new resource for the cardiovascular community. Cardiovascular Research, 2019, 115, e5-e6.	1.8	1
22	Class A Orphans (version 2019.5) in the IUPHAR/BPS Guide to Pharmacology Database. IUPHAR/BPS Guide To Pharmacology CITE, 2019, 2019, .	0.2	8
23	Class A Orphans (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database. IUPHAR/BPS Guide To Pharmacology CITE, 2019, 2019, .	0.2	0
24	Inotropic glutamate receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database. IUPHAR/BPS Guide To Pharmacology CITE, 2019, 2019, .	0.2	1
25	Promoting the clearance of neurotoxic proteins in neurodegenerative disorders of ageing. Nature Reviews Drug Discovery, 2018, 17, 660-688.	21.5	370
26	The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY. Nucleic Acids Research, 2018, 46, D1091-D1106.	6.5	1,584
27	A new nomenclature for classifying psychotropic drugs. British Journal of Clinical Pharmacology, 2017, 83, 1614-1616.	1.1	26
28	THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Overview. British Journal of Pharmacology, 2017, 174, S1-S16.	2.7	269
29	Inhibition of \hat{I}^2 -Glucocerebrosidase Activity Preserves Motor Unit Integrity in a Mouse Model of Amyotrophic Lateral Sclerosis. Scientific Reports, 2017, 7, 5235.	1.6	53
30	I9 IUPHAR: Immunology, metabolism and natural products. Biochemical Pharmacology, 2017, 139, 107.	2.0	0
31	Selective inhibition of extra-synaptic $\hat{I}\pm 5$ -GABA A receptors by S44819, a new therapeutic agent. Neuropharmacology, 2017, 125, 353-364.	2.0	40
32	Behavioural pharmacology of the $\hat{I}\pm 5$ -GABA A receptor antagonist S44819: Enhancement and remediation of cognitive performance in preclinical models. Neuropharmacology, 2017, 125, 30-38.	2.0	17
33	Defining the brain circuits involved in psychiatric disorders: IMI-NEWMEDS. Nature Reviews Drug Discovery, 2017, 16, 1-2.	21.5	35
34	Are We Reaching the Limits of Homo sapiens?. Frontiers in Physiology, 2017, 8, 812.	1.3	52
35	Acute Stress Affects the Expression of Hippocampal Mu Oscillations in an Age-Dependent Manner. Frontiers in Aging Neuroscience, 2017, 9, 295.	1.7	5
36	Sphingolipid Metabolism Is Dysregulated at Transcriptomic and Metabolic Levels in the Spinal Cord of an Animal Model of Amyotrophic Lateral Sclerosis. Frontiers in Molecular Neuroscience, 2017, 10, 433.	1.4	52

#	ARTICLE	IF	CITATIONS
37	Clozapine counteracts a ketamine-induced depression of hippocampal-prefrontal neuroplasticity and alters signaling pathway phosphorylation. <i>PLoS ONE</i> , 2017, 12, e0177036.	1.1	22
38	Species-conserved reconfigurations of brain network topology induced by ketamine. <i>Translational Psychiatry</i> , 2016, 6, e786-e786.	2.4	30
39	The hippocampal to prefrontal cortex circuit in mice: a promising electrophysiological signature in models for psychiatric disorders. <i>Brain Structure and Function</i> , 2016, 221, 2385-2391.	1.2	14
40	The effect of chronic tianeptine administration on the brain mitochondria: direct links with an animal model of depression. <i>Molecular Neurobiology</i> , 2016, 53, 7351-7362.	1.9	21
41	Altering the course of schizophrenia: progress and perspectives. <i>Nature Reviews Drug Discovery</i> , 2016, 15, 485-515.	21.5	410
42	The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. <i>Nucleic Acids Research</i> , 2016, 44, D1054-D1068.	6.5	1,075
43	Alliance between the International Union of Basic and Clinical Pharmacology and the Indian Pharmacological Society for Health, Education, Drug Discovery, and Development in India. <i>Indian Journal of Pharmacology</i> , 2016, 48, 229.	0.4	0
44	The expanding role of immunopharmacology: <sc>IUPHAR</sc> Review 16. <i>British Journal of Pharmacology</i> , 2015, 172, 4217-4227.	2.7	23
45	The Concise Guide to PHARMACOLOGY 2015/16: Overview. <i>British Journal of Pharmacology</i> , 2015, 172, 5729-5743.	2.7	220
46	Creating a specialist protein resource network: a meeting report for the protein bioinformatics and community resources retreat: Figure 1.. Database: the Journal of Biological Databases and Curation, 2015, 2015, bav063.	1.4	8
47	A novel GABAA alpha 5 receptor inhibitor with therapeutic potential. <i>European Journal of Pharmacology</i> , 2015, 764, 497-507.	1.7	23
48	Acute ketamine challenge increases resting state prefrontal-hippocampal connectivity in both humans and rats. <i>Psychopharmacology</i> , 2015, 232, 4231-4241.	1.5	76
49	Key challenges for the creation and maintenance of specialist protein resources. <i>Proteins: Structure, Function and Bioinformatics</i> , 2015, 83, 1005-1013.	1.5	13
50	Amyotrophic lateral sclerosis and denervation alter sphingolipids and up-regulate glucosylceramide synthase. <i>Human Molecular Genetics</i> , 2015, 24, 7390-7405.	1.4	84
51	A review of the current nomenclature for psychotropic agents and an introduction to the Neuroscience-based Nomenclature. <i>European Neuropsychopharmacology</i> , 2015, 25, 2318-2325.	0.3	135
52	The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands. <i>Nucleic Acids Research</i> , 2014, 42, D1098-D1106.	6.5	826
53	Sub-Anesthetic Ketamine Modulates Intrinsic BOLD Connectivity Within the Hippocampal-Prefrontal Circuit in the Rat. <i>Neuropsychopharmacology</i> , 2014, 39, 895-906.	2.8	89
54	Changes in mitochondrial function are pivotal in neurodegenerative and psychiatric disorders: How important is <sc>BDNF</sc>?. <i>British Journal of Pharmacology</i> , 2014, 171, 2206-2229.	2.7	81

#	ARTICLE	IF	CITATIONS
55	A proposal for an updated neuropsychopharmacological nomenclature. <i>European Neuropsychopharmacology</i> , 2014, 24, 1005-1014.	0.3	83
56	Mitochondrial pharmacology: energy, injury and beyond. <i>British Journal of Pharmacology</i> , 2014, 171, 1795-1797.	2.7	10
57	International Union of Basic and Clinical Pharmacology. XC. Multisite Pharmacology: Recommendations for the Nomenclature of Receptor Allosterism and Allosteric Ligands. <i>Pharmacological Reviews</i> , 2014, 66, 918-947.	7.1	189
58	Regulation of AMPA receptor surface trafficking and synaptic plasticity by a cognitive enhancer and antidepressant molecule. <i>Molecular Psychiatry</i> , 2013, 18, 471-484.	4.1	65
59	The Concise Guide to PHARMACOLOGY 2013/14: Overview. <i>British Journal of Pharmacology</i> , 2013, 170, 1449-1458.	2.7	153
60	The hippocampal "prefrontal pathway: The weak link in psychiatric disorders?. <i>European Neuropsychopharmacology</i> , 2013, 23, 1165-1181.	0.3	354
61	Rapid effects of melatonin on hormonal and behavioral stressful responses in ewes. <i>Psychoneuroendocrinology</i> , 2013, 38, 1426-1434.	1.3	21
62	The Concise Guide to PHARMACOLOGY 2013/14: G Protein-Coupled Receptors. <i>British Journal of Pharmacology</i> , 2013, 170, 1459-1581.	2.7	528
63	The Concise Guide to PHARMACOLOGY 2013/14: Enzymes. <i>British Journal of Pharmacology</i> , 2013, 170, 1797-1867.	2.7	416
64	The Concise Guide to PHARMACOLOGY 2013/14: Transporters. <i>British Journal of Pharmacology</i> , 2013, 170, 1706-1796.	2.7	121
65	Egis-11150: A candidate antipsychotic compound with procognitive efficacy in rodents. <i>Neuropharmacology</i> , 2013, 64, 254-263.	2.0	17
66	The low-frequency blood oxygenation level-dependent functional connectivity signature of the hippocampal "prefrontal network in the rat brain. <i>Neuroscience</i> , 2013, 228, 243-258.	1.1	36
67	International Union of Basic and Clinical Pharmacology. LXXXVIII. G Protein-Coupled Receptor List: Recommendations for New Pairings with Cognate Ligands. <i>Pharmacological Reviews</i> , 2013, 65, 967-986.	7.1	250
68	Anti-Correlated Cortical Networks of Intrinsic Connectivity in the Rat Brain. <i>Brain Connectivity</i> , 2013, 3, 503-511.	0.8	55
69	The Concise Guide to PHARMACOLOGY 2013/14: Ligand-Gated Ion Channels. <i>British Journal of Pharmacology</i> , 2013, 170, 1582-1606.	2.7	115
70	The Concise Guide to PHARMACOLOGY 2013/14: Nuclear Hormone Receptors. <i>British Journal of Pharmacology</i> , 2013, 170, 1652-1675.	2.7	90
71	The Concise Guide to PHARMACOLOGY 2013/14: Ion Channels. <i>British Journal of Pharmacology</i> , 2013, 170, 1607-1651.	2.7	226
72	The Concise Guide to PHARMACOLOGY 2013/14: Catalytic Receptors. <i>British Journal of Pharmacology</i> , 2013, 170, 1676-1705.	2.7	148

#	ARTICLE	IF	CITATIONS
73	IUPHAR-DB: updated database content and new features. <i>Nucleic Acids Research</i> , 2013, 41, D1083-D1088.	6.5	94
74	GuideToPharmacology.org – an update. <i>British Journal of Pharmacology</i> , 2012, 167, 697-698.	2.7	3
75	Calling all pharmacologists with time to spare! We need you! Build the drug discovery knowledge base, GuidetoPharmacology.org. <i>British Journal of Pharmacology</i> , 2012, 167, 1393-1394.	2.7	1
76	Run for your life. <i>Nature</i> , 2012, 487, 295-296.	13.7	60
77	Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. <i>Nature Reviews Drug Discovery</i> , 2012, 11, 141-168.	21.5	960
78	Brain-derived neurotrophic factor-mediated effects on mitochondrial respiratory coupling and neuroprotection share the same molecular signalling pathways. <i>European Journal of Neuroscience</i> , 2012, 35, 366-374.	1.2	93
79	Emotional memory impairments in a genetic rat model of depression: involvement of 5-HT/MEK/Arc signaling in restoration. <i>Molecular Psychiatry</i> , 2012, 17, 173-184.	4.1	68
80	Design, synthesis and pharmacological evaluation of new series of naphthalenic analogues as melatonergic (MT1/MT2) and serotonergic 5-HT _{2C} dual ligands (I). <i>European Journal of Medicinal Chemistry</i> , 2012, 49, 310-323.	2.6	29
81	Multiple exposures to familiar conspecific withdrawal is a novel robust stress paradigm in ewes. <i>Physiology and Behavior</i> , 2012, 105, 203-208.	1.0	19
82	Optimization of (Arylpiperazinylbutyl)oxindoles Exhibiting Selective 5-HT ₇ Receptor Antagonist Activity. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 6657-6669.	2.9	47
83	Tianeptine potentiates AMPA receptors by activating CaMKII and PKA via the p38, p42/44 MAPK and JNK pathways. <i>Neurochemistry International</i> , 2011, 59, 1109-1122.	1.9	25
84	Resolution of controversies in drug/receptor interactions by protein structure. Limitations and pharmacological solutions. <i>Neuropharmacology</i> , 2011, 60, 3-6.	2.0	12
85	Introduction to the special issue on High Resolution Neuropharmacology. <i>Neuropharmacology</i> , 2011, 60, 1-2.	2.0	1
86	The protective effect of tianeptine on Gp120-induced apoptosis in astroglial cells: role of GS and NOS, and NF- κ B suppression. <i>British Journal of Pharmacology</i> , 2011, 164, 1590-1599.	2.7	26
87	IUPHAR-DB: new receptors and tools for easy searching and visualization of pharmacological data. <i>Nucleic Acids Research</i> , 2011, 39, D534-D538.	6.5	96
88	IUPHAR-DB: the IUPHAR database of G protein-coupled receptors and ion channels. <i>Nucleic Acids Research</i> , 2009, 37, D680-D685.	6.5	199
89	Influence of the novel antidepressant and melatonin agonist/serotonin _{2C} receptor antagonist, agomelatine, on the rat sleep-wake cycle architecture. <i>Psychopharmacology</i> , 2009, 205, 93-106.	1.5	39
90	GAP-43 is essential for the neurotrophic effects of BDNF and positive AMPA receptor modulator S18986. <i>Cell Death and Differentiation</i> , 2009, 16, 624-637.	5.0	58

#	ARTICLE	IF	CITATIONS
91	A nomenclature for ligand-gated ion channels. <i>Neuropharmacology</i> , 2009, 56, 2-5.	2.0	531
92	Antidepressants reverse the attenuation of the neurotrophic MEK/MAPK cascade in frontal cortex by elevated platform stress; reversal of effects on LTP is associated with GluA1 phosphorylation. <i>Neuropharmacology</i> , 2009, 56, 37-46.	2.0	91
93	Editorial. <i>Neuropharmacology</i> , 2009, 56, 1.	2.0	23
94	The AMPA receptor positive allosteric modulator, S18986, is neuroprotective against neonatal excitotoxic and inflammatory brain damage through BDNF synthesis. <i>Neuropharmacology</i> , 2009, 57, 277-286.	2.0	25
95	Drugs in sport: a scientist's perspective: from ambition to neurochemistry. <i>British Journal of Pharmacology</i> , 2008, 154, 496-501.	2.7	15
96	Agomelatine, a melatonin receptor agonist with 5-HT _{2C} receptor antagonist properties, protects the developing murine white matter against excitotoxicity. <i>European Journal of Pharmacology</i> , 2008, 588, 58-63.	1.7	45
97	(Phenylpiperazinyl-butyl)oxindoles as Selective 5-HT ₇ Receptor Antagonists. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 2522-2532.	2.9	86
98	2,3-Benzodiazepine-type AMPA receptor antagonists and their neuroprotective effects. <i>Neurochemistry International</i> , 2008, 52, 166-183.	1.9	39
99	Protection of stress-induced impairment of hippocampal/prefrontal LTP through blockade of glucocorticoid receptors. <i>Experimental Neurology</i> , 2008, 211, 593-596.	2.0	43
100	Neurotrophins and Cytokines in Neuronal Plasticity. <i>Novartis Foundation Symposium</i> , 2008, 289, 222-237.	1.2	56
101	International Union of Basic and Clinical Pharmacology. LXVII. Recommendations for the Recognition and Nomenclature of G Protein-Coupled Receptor Heteromultimers. <i>Pharmacological Reviews</i> , 2007, 59, 5-13.	7.1	274
102	Functional Selectivity and Classical Concepts of Quantitative Pharmacology. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007, 320, 1-13.	1.3	997
103	Clinical trials in neonates: Ethical issues. <i>Seminars in Fetal and Neonatal Medicine</i> , 2007, 12, 318-323.	1.1	14
104	How can drug discovery for psychiatric disorders be improved?. <i>Nature Reviews Drug Discovery</i> , 2007, 6, 189-201.	21.5	217
105	Involvement of AMPA receptor phosphorylation in antidepressant actions with special reference to tianeptine. <i>European Journal of Neuroscience</i> , 2007, 26, 3509-3517.	1.2	116
106	Overview of Nomenclature of Nuclear Receptors. <i>Pharmacological Reviews</i> , 2006, 58, 685-704.	7.1	540
107	Endocannabinoids potently protect the newborn brain against AMPA-kainate receptor-mediated excitotoxic damage. <i>British Journal of Pharmacology</i> , 2006, 148, 442-451.	2.7	56
108	Common efficacy of psychotropic drugs in restoring stress-induced impairment of prefrontal plasticity. <i>Neurotoxicity Research</i> , 2006, 10, 193-198.	1.3	31

#	ARTICLE	IF	CITATIONS
109	New directions for drug discovery. <i>Dialogues in Clinical Neuroscience</i> , 2006, 8, 295-301.	1.8	13
110	A pathophysiological paradigm for the therapy of psychiatric disease. <i>Nature Reviews Drug Discovery</i> , 2005, 4, 467-476.	21.5	70
111	The effects of AMPA receptor antagonists in models of stroke and neurodegeneration. <i>European Journal of Pharmacology</i> , 2005, 519, 58-67.	1.7	34
112	International Union of Pharmacology. XLVI. G Protein-Coupled Receptor List. <i>Pharmacological Reviews</i> , 2005, 57, 279-288.	7.1	452
113	International Union of Pharmacology. LVI. Ghrelin Receptor Nomenclature, Distribution, and Function. <i>Pharmacological Reviews</i> , 2005, 57, 541-546.	7.1	215
114	Chronic restraint stress up-regulates GLT-1 mRNA and protein expression in the rat hippocampus: Reversal by tianeptine. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 2179-2184.	3.3	199
115	Current status of drug receptor nomenclature: receptor closure? The role of NC-IUPHAR. <i>Expert Opinion on Investigational Drugs</i> , 2004, 13, 461-464.	1.9	1
116	Acute Stress-induced Changes in Hippocampal/Prefrontal Circuits in Rats: Effects of Antidepressants. <i>Cerebral Cortex</i> , 2004, 14, 224-229.	1.6	270
117	BDNF increases rat brain mitochondrial respiratory coupling at complex I, but not complex II. <i>European Journal of Neuroscience</i> , 2004, 20, 1189-1196.	1.2	122
118	Plasticity at hippocampal to prefrontal cortex synapses is impaired by loss of dopamine and stress: Importance for psychiatric diseases. <i>Neurotoxicity Research</i> , 2004, 6, 233-244.	1.3	123
119	Strategies for neuroprotection in the newborn. <i>Drug Discovery Today: Therapeutic Strategies</i> , 2004, 1, 77-82.	0.5	7
120	P2-009 The positive allosteric modulator of AMPA receptors, S 18986, is neuroprotective in neonatal mouse brain: interaction with neurotrophins. <i>Neurobiology of Aging</i> , 2004, 25, S226.	1.5	0
121	Up and Down Regulation of Synaptic Strength at Hippocampal to Prefrontal Cortex Synapses. , 2004, , 107-130.		3
122	Effects of EGIS-7625, a Selective and Competitive 5-HT _{2B} Receptor Antagonist. <i>Cardiovascular Drugs and Therapy</i> , 2003, 17, 427-434.	1.3	6
123	Positive allosteric modulators of AMPA receptors are neuroprotective against lesions induced by an NMDA agonist in neonatal mouse brain. <i>Brain Research</i> , 2003, 970, 221-225.	1.1	72
124	The glycine transporter-1 inhibitors NFPS and Org 24461: a pharmacological study. <i>Pharmacology Biochemistry and Behavior</i> , 2003, 74, 811-825.	1.3	99
125	International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on Terms and Symbols in Quantitative Pharmacology. <i>Pharmacological Reviews</i> , 2003, 55, 597-606.	7.1	536
126	Neuroprotective properties of tianeptine: interactions with cytokines. <i>Neuropharmacology</i> , 2003, 44, 801-809.	2.0	39

#	ARTICLE	IF	CITATIONS
127	Brain plasticity and pathology in psychiatric disease: sites of action for potential therapy. <i>Current Opinion in Pharmacology</i> , 2003, 3, 33-40.	1.7	43
128	Mss4Gene Is Up-Regulated in Rat Brain after Chronic Treatment with Antidepressant and Down-Regulated When Rats Are Anhedonic. <i>Molecular Pharmacology</i> , 2002, 62, 1332-1338.	1.0	22
129	Role of spin trapping and P2Y receptor antagonism in the neuroprotective effects of 2,2â€²-pyridylisatogen tosylate and related compounds. <i>European Journal of Pharmacology</i> , 2002, 444, 53-60.	1.7	8
130	Effects of phencyclidine (PCP) and MK 801 on the EEGq in the prefrontal cortex of conscious rats; antagonism by clozapine, and antagonists of AMPA-, ± 1 - and 5-HT2A -receptors. <i>British Journal of Pharmacology</i> , 2002, 135, 65-78.	2.7	57
131	S 14506: novel receptor coupling at 5-HT1A receptors. <i>Neuropharmacology</i> , 2001, 40, 334-344.	2.0	24
132	Mitochondria as target for antiischemic drugs. <i>Advanced Drug Delivery Reviews</i> , 2001, 49, 151-174.	6.6	74
133	The neuroprotective activity of 8-alkylamino-1,4-benzoxazine antioxidants. <i>European Journal of Pharmacology</i> , 2001, 424, 189-194.	1.7	29
134	Neuroprotection in the newborn infant: interactions between stress, glutamate, glucocorticoids and development. <i>Developmental Medicine and Child Neurology</i> , 2001, 43, 10-12.	1.1	1
135	A One-Step Synthesis of 2-(2-Pyridyl)-3H-indol-3-oneN-Oxide:Â Is It an Efficient Spin Trap for Hydroxyl Radical?. <i>Journal of Organic Chemistry</i> , 2000, 65, 4460-4463.	1.7	50
136	Changes in EEG spectral power in the prefrontal cortex of conscious rats elicited by drugs interacting with dopaminergic and noradrenergic transmission. <i>British Journal of Pharmacology</i> , 1999, 128, 1045-1054.	2.7	72
137	A Three Binding Site Hypothesis for the Interaction of Ligands with Monoamine G Protein-coupled Receptors: Implications for Combinatorial Ligand Design. <i>QSAR and Combinatorial Science</i> , 1999, 18, 561-572.	1.4	30
138	Neuroprotective effects of modulators of P2 receptors in primary culture of CNS neurones. <i>Neuropharmacology</i> , 1999, 38, 1335-1342.	2.0	49
139	A Unified Nomenclature System for the Nuclear Receptor Superfamily. <i>Cell</i> , 1999, 97, 161-163.	13.5	1,083
140	4H-1,2,4-Pyridothiadiazine 1,1-Dioxides and 2,3-Dihydro-4H-1,2,4-pyridothiadiazine 1,1-Dioxides Chemically Related to Diazoxide and Cyclothiazide as Powerful Positive Allosteric Modulators of (R/S)-2-Amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propionic Acid Receptors:Â Design, Synthesis, Pharmacology, and Structureâ€™Activity Relationships. <i>Journal of Medicinal Chemistry</i> , 1998, 41, 2946-2959.	2.9	65
141	Acylation Differentiates Two Forms of Agonist Binding to Rat 5-HT1AReceptors.. <i>Annals of the New York Academy of Sciences</i> , 1997, 812, 178-178.	1.8	0
142	Transduction Is a Major Factor Influencing Receptor Characterization. <i>Annals of the New York Academy of Sciences</i> , 1997, 812, 29-40.	1.8	6
143	Inhibition of the constitutive activity of human 5-HT1A receptors by the inverse agonist, spiperone but not the neutral antagonist, WAY 100,635. <i>British Journal of Pharmacology</i> , 1997, 120, 737-739.	2.7	80
144	Developments in purine and pyrimidine receptor-based therapeutics. <i>Drug Development Research</i> , 1996, 39, 436-441.	1.4	18

#	ARTICLE	IF	CITATIONS
145	Receptor nomenclature. Drug Development Research, 1996, 39, 461-466.	1.4	18
146	Neuroprotective properties of lifarizine compared with those of other agents in a mouse model of focal cerebral ischaemia. British Journal of Pharmacology, 1995, 115, 1425-1432.	2.7	20
147	Clozapine inhibits serotonergic transmission by an action at $\hat{1}\pm$ 1-adrenoceptors not at 5-HT1A receptors. European Journal of Pharmacology, 1994, 260, 79-83.	1.7	47
148	S 14297, a novel selective ligand at cloned human dopamine D3 receptors, blocks 7-OH-DPAT-induced hypothermia in rats. European Journal of Pharmacology, 1994, 260, R3-R5.	1.7	49
149	$\hat{1}\pm$ 2-Adrenoceptors: more subtypes but fewer functional differences. Trends in Pharmacological Sciences, 1994, 15, 119-123.	4.0	90
150	[3H]p-Aminoclonidine and [3H]idazoxan label different populations of imidazoline sites on rat kidney. European Journal of Pharmacology, 1993, 232, 79-87.	1.7	42
151	Changes in [³ H]â€”PK 11195 and [³ H]â€”OHâ€”DPAT binding following forebrain ischaemia in the gerbil. British Journal of Pharmacology, 1993, 109, 437-442.	2.7	3
152	Channel nomenclature: IUPHAR recommendations. Trends in Pharmacological Sciences, 1993, 14, 435-436.	4.0	0
153	Anti-inflammatory actions of steroids: molecular mechanisms. Trends in Pharmacological Sciences, 1993, 14, 436-441.	4.0	687
154	Modulation of $\hat{1}\pm$ 1-Adrenoceptors in Rat Left Ventricle by Ischaemia and Acyl Carnitines. Journal of Cardiovascular Pharmacology, 1993, 21, 869-873.	0.8	43
155	Voltage-dependent calcium channels: structures and drug-binding sites. Biochemical Society Transactions, 1992, 20, 147-153.	1.6	6
156	Classification of calcium channels and calcium antagonists: Progress report. Cardiovascular Drugs and Therapy, 1992, 6, 35-39.	1.3	10
157	Role of Lipids and Lipid Metabolites in Myocardial Ischaemia. , 1992, , 170-188.		2
158	The guineaâ€”pig ileum preparation as a model for 5â€”HT_{1A} receptors: anomalous effects with RSâ€”30199â€”193. British Journal of Pharmacology, 1991, 104, 519-525.	2.7	6
159	Structure-affinity relationships of 12-sulfonyl derivatives of 5,8,8a,9,10,11,12,12a,13,13a-decahydro-6H-isoquino[2,1-g][1,6]naphthyridines at .alpha.-adrenoceptors. Journal of Medicinal Chemistry, 1991, 34, 705-717.	2.9	27
160	Affinity of 2-(tetrahydroisoquinolin-2-ylmethyl)- and 2-(isoindolin-2-ylmethyl)imidazolines for .alpha.-adrenoceptors. Differential affinity of imidazolines for the [3H]idazoxan-labeled .alpha.2-adrenoceptor vs the [3H]yohimbine-labeled site. Journal of Medicinal Chemistry, 1990, 33, 596-600.	2.9	11
161	1,9-Alkano-bridged 2,3,4,5-tetrahydro-1H-3-benzazepines with affinity for the .alpha.2-adrenoceptor and the 5-HT1A receptor. Journal of Medicinal Chemistry, 1990, 33, 633-641.	2.9	43
162	$\hat{1}\pm$ ₂-â€”Adrenoceptor subtypes and imidazolineâ€”like binding sites in the rat brain. British Journal of Pharmacology, 1990, 99, 803-809.	2.7	109

#	ARTICLE	IF	CITATIONS
163	The influence of the initial stretch and the agonist-induced tone on the effect of basal and stimulated release of EDRF. <i>British Journal of Pharmacology</i> , 1990, 100, 767-773.	2.7	52
164	Selective antagonism of calcium channel activators by fluspirilene. <i>British Journal of Pharmacology</i> , 1990, 100, 211-216.	2.7	14
165	The \pm 2-adrenoceptor antagonist SK & F 104078 has high affinity for 5-HT _{1A} and 5-HT ₂ receptors. <i>European Journal of Pharmacology</i> , 1989, 166, 315-318.	1.7	3
166	The effects of calcium antagonists on calcium overload contractures in embryonic chick myocytes induced by ouabain and veratrine. <i>British Journal of Pharmacology</i> , 1989, 97, 83-94.	2.7	22
167	Interaction of palmitoyl carnitine with calcium antagonists in myocytes. <i>British Journal of Pharmacology</i> , 1989, 97, 443-450.	2.7	20
168	(8 α .,12 α .,13 α .)-5,8,9,10,11,12,12 α ,13,13 α -Decahydro-3-methoxy-12-(methylsulfonyl)-6H-isoquino[2,1-g][1,6]naph a potent and highly selective α .2-adrenoceptor antagonist. <i>Journal of Medicinal Chemistry</i> , 1989, 32, 2034-2036.	2.9	41
169	Antagonists and Activators at Calcium Channels.. <i>Annals of the New York Academy of Sciences</i> , 1988, 522, 248-258.	1.8	12
170	Calcium Antagonist Properties of Diclofurime Isomers. II. Molecular Aspects. <i>Journal of Cardiovascular Pharmacology</i> , 1987, 9, 469-477.	0.8	23
171	Interaction of phorbol esters with Ca ²⁺ channels in smooth muscle. <i>British Journal of Pharmacology</i> , 1987, 91, 377-384.	2.7	25
172	Direct activation of Ca ²⁺ channels by palmitoyl carnitine, a putative endogenous ligand. <i>British Journal of Pharmacology</i> , 1987, 92, 457-468.	2.7	71
173	Calcium Channel Activation Does Not Increase Release of Endothelial-Derived Relaxant Factors (EDRF) in Rat Aorta Although Tonic Release of EDRF May Modulate Calcium Channel Activity in Smooth Muscle. <i>Journal of Cardiovascular Pharmacology</i> , 1986, 8, 1130-1137.	0.8	61
174	A functional correlate for the dihydropyridine binding site in rat brain. <i>Nature</i> , 1985, 314, 94-96.	13.7	252
175	Competitive interactions between Bay K 8644 and nifedipine in K ⁺ depolarized smooth muscle: a passive role for Ca ²⁺ ?. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 1985, 328, 464-466.	1.4	31
176	Differential effects of calcium channel antagonists on histamine and pentagastrin-stimulated gastric acid secretion in the rat. <i>Agents and Actions</i> , 1985, 16, 491-495.	0.7	10
177	Calcium antagonist subgroups. <i>Trends in Pharmacological Sciences</i> , 1985, 6, 109-114.	4.0	145
178	Antagonism of Ca ²⁺ -induced contractions of K ⁺ -depolarized smooth muscle by local anaesthetics. <i>European Journal of Pharmacology</i> , 1985, 108, 143-150.	1.7	30
179	Interactions between a ?calcium channel agonist?, Bay K 8644, and calcium antagonists differentiate calcium antagonist subgroups in K ⁺ -depolarized smooth muscle. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 1984, 328, 69-75.	1.4	69
180	â€œCalcium antagonistsâ€ A class of drugs with a bright future. Part II. Determination of basic pharmacological properties. <i>Life Sciences</i> , 1984, 35, 575-587.	2.0	75

#	ARTICLE	IF	CITATIONS
181	Changing surface charge with salicylate differentiates between subgroups of calcium antagonists. British Journal of Pharmacology, 1984, 83, 211-220.	2.7	32
182	“Calcium antagonists” A class of drugs with a bright future. Part I. Cellular calcium homeostasis and calcium as a coupling messenger. Life Sciences, 1983, 33, 2571-2581.	2.0	53
183	Direct inhibitory effects of some calcium antagonists™ and trifluoperazine on the contractile proteins in smooth muscle. British Journal of Pharmacology, 1983, 79, 225-231.	2.7	78
184	Functional interactions of calcium antagonists in K ⁺ -depolarized smooth muscle. British Journal of Pharmacology, 1983, 80, 485-488.	2.7	15
185	Differences Between the Effects of Calcium Antagonists in the Pithed Rat Preparation. Journal of Cardiovascular Pharmacology, 1982, 4, 973-979.	0.8	23
186	Assessment of Ca ²⁺ -antagonist effects of drugs in K ⁺ -depolarized smooth muscle. Naunyn-Schmiedeberg's Archives of Pharmacology, 1982, 318, 234-240.	1.4	142
187	IDENTIFICATION OF SEPARATE RECEPTORS FOR ADENOSINE AND ADENOSINE 5'-TRIPHOSPHATE IN CAUSING RELAXATIONS OF THE ISOLATED TAENIA OF THE GUINEA PIG CAECUM. British Journal of Pharmacology, 1976, 57, 305-310.	2.7	48
188	ANTAGONISM OF ADENOSINE 5'-TRIPHOSPHATE-INDUCED RELAXATION BY 2-PYRIDYLISATOGEN IN THE TAENIA OF GUINEA PIG CAECUM. British Journal of Pharmacology, 1975, 53, 575-583.	2.7	65
189	In search of the mechanisms of ketamine™s antidepressant effects: How robust is the evidence behind the mTor activation hypothesis. F1000Research, 0, 5, 634.	0.8	28